Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
953 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (495)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06858501 | Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma | withdrawn | Phase 2 | 0 | Children's Oncology GroupNETWORK | 0 | Sep 16, 2026 | clinicaltrials |
| NCT05218408 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type(CYNK001GBM02) | withdrawn | Phase 1 / Phase 2 | 0 | Celularity IncorporatedINDUSTRY | 0 | Jun 8, 2026 |
| NCT04105374 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma | withdrawn | Phase 2 / Phase 3 | 0 | NRG OncologyOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT04482933 | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | withdrawn | Phase 2 | 0 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04118036 | Abemaciclib + Pembrolizumab In Glioblastoma | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06233903 | 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System | withdrawn | Phase 2 | 0 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)INDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06308575 | A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 10, 2025 | clinicaltrials |
| NCT06328036 | Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 30, 2024 | clinicaltrials |
| NCT05973903 | Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Tel Aviv Medical CenterOTHER | 0 | Dec 4, 2024 | clinicaltrials |
| NCT05879120 | Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06182410 | Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 0 | Aug 7, 2024 | clinicaltrials |
| NCT01622764 | 89Zr-RO5323441 PET Imaging in Glioblastoma | withdrawn | Phase 2 | 0 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT04629209 | A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT02432417 | The Addition of Chloroquine to Chemoradiation for Glioblastoma, | withdrawn | Phase 2 | 0 | Maastricht Radiation OncologyOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT04427228 | Single vs Multi-fraction SRS Patients on Immunotherapy(MIGRAINE) | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT03649464 | Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants | withdrawn | Phase 1 / Phase 2 | 0 | Oblato, Inc.INDUSTRY | 0 | Oct 7, 2022 | clinicaltrials |
| NCT04909515 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. | withdrawn | Phase 2 | 0 | Y-mAbs TherapeuticsINDUSTRY | 4 | Sep 1, 2022 | clinicaltrials |
| NCT04315246 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) | withdrawn | Phase 1 / Phase 2 | 0 | Y-mAbs TherapeuticsINDUSTRY | 2 | Jul 15, 2022 | clinicaltrials |
| NCT04065087 | Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Genexine, Inc.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT02283944 | TMS Electrochemotherapy for Glioblastoma Multiforme | withdrawn | Phase 2 | 0 | University of AarhusOTHER | 0 | Sep 20, 2021 | clinicaltrials |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03506139 | Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma | withdrawn | Phase 2 | 0 | John M. BuattiOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03014804 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03973879 | Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma | withdrawn | Phase 1 / Phase 2 | 0 | Darell BignerOTHER | 0 | Feb 11, 2020 | clinicaltrials |
| NCT02754362 | A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT00984438 | Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme | withdrawn | Phase 1 / Phase 2 | 0 | University of CincinnatiOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT03632317 | A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT03120000 | PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | withdrawn | Phase 2 | 0 | PIQUR Therapeutics AGINDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03212807 | Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL(DuRIANS) | withdrawn | Phase 2 | 0 | Singapore General HospitalOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT02011126 | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors | withdrawn | Phase 2 | 0 | Children's Oncology GroupNETWORK | 0 | Aug 7, 2018 | clinicaltrials |
| NCT01788280 | Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab | withdrawn | Phase 2 | 0 | University of UtahOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT01740570 | Phase I/II Cabazitaxel for Recurrent Malignant Glioma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 19, 2018 | clinicaltrials |
| NCT01782976 | Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 19, 2018 | clinicaltrials |
| NCT02348255 | NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse | withdrawn | Phase 2 | 0 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT03013387 | Dosimetry Guided PRRT With 90Y-DOTATOC | withdrawn | Phase 2 | 0 | Sue O'DorisioOTHER | 0 | Aug 25, 2017 | clinicaltrials |
| NCT01413438 | Bevacizumab With or Without Surgery for Adult Glioblastomas | withdrawn | Phase 2 | 0 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 0 | Jul 2, 2017 | clinicaltrials |
| NCT02876003 | Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma | withdrawn | Phase 2 | 0 | GenSpera, Inc.INDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT01048086 | 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) | withdrawn | Phase 2 | 0 | University of IowaOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01445691 | More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery | withdrawn | Phase 2 | 0 | Constantinos HadjipanayisOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT01249105 | MK-2206 for Recurrent Malignant Glioma | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT02521090 | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Feb 15, 2016 | clinicaltrials |
| NCT00003273 | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 3 | Dec 3, 2015 | clinicaltrials |
| NCT00992173 | Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma | withdrawn | Phase 2 | 0 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 2 | Nov 26, 2015 | clinicaltrials |
| NCT02599090 | Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 6, 2015 | clinicaltrials |
| NCT00874315 | Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL. | withdrawn | Phase 2 | 0 | Nationwide Children's HospitalOTHER | 1 | Oct 16, 2015 | clinicaltrials |
| NCT01174537 | New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Hadassah Medical OrganizationOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT01225510 | A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | PfizerINDUSTRY | 0 | Mar 11, 2015 | clinicaltrials |
| NCT00378235 | Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma | withdrawn | Phase 1 / Phase 2 | 0 | INSYS Therapeutics IncINDUSTRY | 1 | Nov 13, 2014 | clinicaltrials |
| NCT01952886 | Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients | withdrawn | Phase 2 | 0 | Duke UniversityOTHER | 1 | Sep 22, 2014 | clinicaltrials |
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials